Sign up to save your podcasts
Or
Share How Tumor-on-a-Chip Technology Is Transforming Cancer Treatment and Drug Testing
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How Tumor-on-a-Chip Technology Is Transforming Cancer Treatment and Drug Testing
What if the tools we use to test cancer drugs don’t behave like human tumors at all?
That’s the question that pushed Ghazaleh Madani, CEO and co-founder of CanChips, to build one of the most compelling innovations in oncology today: tumor-on-a-chip platforms that replicate human tumor biology with unprecedented accuracy.
In this episode, we explore how microfluidics, 3D co-cultures, endothelial layers, and real-time biosensing combine to replace outdated 2D cultures and reduce reliance on animal models.
The result: faster, more predictive cancer drug testing — and a pathway toward truly personalized oncology.
Our sponsor:
🚀 Exclusive Black Friday offer – NordStellar x Startuprad.io. NordStellar, developed by the team behind NordVPN, gives startups and scaleups real-time insights into leaked credentials, darknet threats, and unprotected assets – before attackers can exploit them.
👉 Get 20% off with code blackfriday20 at nordstellar.com/startupradio.
🕒 Offer valid until December 10, 2025 – protect your business before your data is offered for sale on the darknet. NordStellar – Know what attackers know. Act first.
You’ll learn:
– Why 2D cultures and animal models fail
– How tumor-on-chip platforms replicate human tumor environments
– How patient-derived cells lead to 72-hour drug response predictions
– What this means for biotech founders, pharma teams, and investors
– How German startups are shaping deep-tech innovation in the DACH region
– What it takes to build and lead a cross-disciplinary biotech team
– Why founder visibility matters as much as scientific rigor
Whether you're building in Germany, Austria, or Switzerland, this episode offers one of the clearest explanations of capital-efficient growth, B2B startup scaling, and long-term founder wealth creation.
Guest Spotlight
Ghazaleh Madani is a biotech founder whose mission began when her mother was diagnosed with cancer. Her work at CanChips merges engineering, biology, and human urgency — delivering one of the most promising tumor-modeling systems in Europe.
If this episode helped you, follow the podcast and share it with a founder who needs this playbook.
Enjoy the show?
📖 Blog recap: https://www.startuprad.io/post/tumor-on-a-chip-explained-the-future-of-cancer-drug-testing
Watch on YouTube: https://youtu.be/JIow-O-AM50
🎧 The Audio Podcast
Subscribe here: https://linktr.ee/startupradio
🚪 Connect with Us
Partner with us: [email protected]
Subscribe: https://linktr.ee/startupradio
Feedback: https://forms.gle/SrcGUpycu26fvMFE9
Follow Joe on LinkedIn: http://www.linkedin.com/comm/mynetwork/discovery-see-all?usecase=PEOPLE_FOLLOWS&followMember=joernmenninger
View all episodes
By Startuprad.io™ – Europe’s Startup & VC Podcast NetworkWhat if the tools we use to test cancer drugs don’t behave like human tumors at all?
That’s the question that pushed Ghazaleh Madani, CEO and co-founder of CanChips, to build one of the most compelling innovations in oncology today: tumor-on-a-chip platforms that replicate human tumor biology with unprecedented accuracy.
In this episode, we explore how microfluidics, 3D co-cultures, endothelial layers, and real-time biosensing combine to replace outdated 2D cultures and reduce reliance on animal models.
The result: faster, more predictive cancer drug testing — and a pathway toward truly personalized oncology.
Our sponsor:
🚀 Exclusive Black Friday offer – NordStellar x Startuprad.io. NordStellar, developed by the team behind NordVPN, gives startups and scaleups real-time insights into leaked credentials, darknet threats, and unprotected assets – before attackers can exploit them.
👉 Get 20% off with code blackfriday20 at nordstellar.com/startupradio.
🕒 Offer valid until December 10, 2025 – protect your business before your data is offered for sale on the darknet. NordStellar – Know what attackers know. Act first.
You’ll learn:
– Why 2D cultures and animal models fail
– How tumor-on-chip platforms replicate human tumor environments
– How patient-derived cells lead to 72-hour drug response predictions
– What this means for biotech founders, pharma teams, and investors
– How German startups are shaping deep-tech innovation in the DACH region
– What it takes to build and lead a cross-disciplinary biotech team
– Why founder visibility matters as much as scientific rigor
Whether you're building in Germany, Austria, or Switzerland, this episode offers one of the clearest explanations of capital-efficient growth, B2B startup scaling, and long-term founder wealth creation.
Guest Spotlight
Ghazaleh Madani is a biotech founder whose mission began when her mother was diagnosed with cancer. Her work at CanChips merges engineering, biology, and human urgency — delivering one of the most promising tumor-modeling systems in Europe.
If this episode helped you, follow the podcast and share it with a founder who needs this playbook.
Enjoy the show?
📖 Blog recap: https://www.startuprad.io/post/tumor-on-a-chip-explained-the-future-of-cancer-drug-testing
Watch on YouTube: https://youtu.be/JIow-O-AM50
🎧 The Audio Podcast
Subscribe here: https://linktr.ee/startupradio
🚪 Connect with Us
Partner with us: [email protected]
Subscribe: https://linktr.ee/startupradio
Feedback: https://forms.gle/SrcGUpycu26fvMFE9
Follow Joe on LinkedIn: http://www.linkedin.com/comm/mynetwork/discovery-see-all?usecase=PEOPLE_FOLLOWS&followMember=joernmenninger